PBT2 in postoperative delirium ?????, page-25

"Once these results are confirmed, PBT2 would become the only compound tested in Alzheimer’s-in-a-Dish to achieve all three of these effects on AD pathology" From the AGM presentation.
Do you understand "the only compound" part.

[Tanzi, a four-time BrightFocus grant recipient, is already using the new method to test 1,200 drugs currently on the market and 5,000 experimental drugs that have made it through the first phase of clinical testing. The next steps are to evaluate dosing and effectiveness, and there is hope that the petri dish approach will narrow the field to only the most promising candidates.

To attempt a screening of this type and at this scale in mouse studies would be nearly impossible, making this an exciting time for Alzheimer’s research."] Thanks Pierre for this link.

http://www.brightfocus.org/alzheimers/article/alzheimers-petri-dish

Is it coming clear to you yet just how good this MPAC platform is. The next step to "evaluate dosing and effectiveness" To me this has great potential. We know from the Lindquist work that the most efficacy was seen just before toxicity. The Whitehead were able to push that boundary because it was just yeast cells. Now Tanzi can do it with PBT2 or any other MPAC on live human AD affected neurons.